Insmed Incorporated
Clinical trials sponsored by Insmed Incorporated, explained in plain language.
-
New drug access for lung disease patients
Disease control APPROVED_FOR_MARKETINGThis study provides early access to brensocatib for people with non-cystic fibrosis bronchiectasis, a chronic lung condition. Participants must have successfully completed the earlier ASPEN trial and received brensocatib before. The goal is to continue managing the disease, not t…
Sponsor: Insmed Incorporated • Aim: Disease control
Last updated May 17, 2026 02:39 UTC
-
New hope for painful skin condition: brensocatib enters phase 2b trial
Disease control OngoingThis study tests whether brensocatib can reduce painful bumps and abscesses in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. About 214 participants will receive either the drug or a placebo for 16 weeks. The main goal is to see if brensoc…
Phase: PHASE2 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New inhaled drug shows promise for lung disease patients in Long-Term trial
Disease control OngoingThis study looks at the long-term safety of an inhaled powder called TPIP for people with pulmonary arterial hypertension (PAH), a serious lung condition. About 91 adults who completed earlier TPIP studies will take the drug and be monitored for side effects and changes in walkin…
Phase: PHASE2, PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC